<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2709-7927</journal-id>
<journal-title><![CDATA[Acta Médica del Centro]]></journal-title>
<abbrev-journal-title><![CDATA[Acta méd centro]]></abbrev-journal-title>
<issn>2709-7927</issn>
<publisher>
<publisher-name><![CDATA[Hospital Provincial Clínico Quirúrgico Universitario Arnaldo Milián Castro]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2709-79272020000400517</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Caracterización clínica-demográfica y de eventos adversos durante el tratamiento con Heberprot-P]]></article-title>
<article-title xml:lang="en"><![CDATA[Clinical-demographic and adverse-event characterization during treatment with Heberprot-P]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Trujillo Pedroza]]></surname>
<given-names><![CDATA[Perla María]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mendoza Molina]]></surname>
<given-names><![CDATA[Asiris]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rivalta Morfa]]></surname>
<given-names><![CDATA[Magdenis]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[George Arce]]></surname>
<given-names><![CDATA[Maite]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Castellón Martínez]]></surname>
<given-names><![CDATA[Linnet]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Policlínico Docente &#8220;Manuel Piti Fajardo&#8221;  ]]></institution>
<addr-line><![CDATA[Santo Domingo Villa Clara]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2020</year>
</pub-date>
<volume>14</volume>
<numero>4</numero>
<fpage>517</fpage>
<lpage>529</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S2709-79272020000400517&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S2709-79272020000400517&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S2709-79272020000400517&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  el Heberprot-P es un novedoso medicamento que ha llegado para la reducción de los riesgos de amputación; como cualquier medicamento no está desprovisto de eventos adversos.  Objetivos:  caracterizara los pacientes durante el tratamiento con Heberprot-P de acuerdo a variables demográficas y clínicas, así como describir los eventos adversos informados durante la terapia.  Métodos:  se realizó en la Consulta de Atención Integral al paciente con úlceras del pie diabético del &#8220;Policlínico Manuel Piti Fajardo&#8221; de Santo Domingo, Villa Clara, un estudio longitudinal entre enero de 2017 y septiembre de 2019. La muestra fue de 104 pacientes a los que se les aplicó el Heberprot-P. Se utilizaron las variables: edad, sexo, clasificación de Wagner, clasificación etiopatogénica del pie diabético, efectividad del tratamiento y eventos adversos informados (se trataron la frecuencia, la intensidad, la gravedad y la relación de causalidad).  Resultados:  predominaron las féminas y los pacientes con más de 60 años (67,31%). Prevalecieron, según la clasificación de Wagner para la úlcera de pie diabético, el grado 1 (73,08%), y según la etiopatogenia, los pacientes con pie neuroinfeccioso (58,65%).Se apreció una efectividad total del 90,38% al tratamiento. Los eventos adversos más frecuentes fueron el ardor, el dolor y la cefalea. Predominaron los eventos adversos dependientes del modo de administración y del producto en si (ardor y dolor), en su mayoría de intensidad leve y causalidad definida.  Conclusiones:  se confirmó el efecto beneficioso del Heberprot-P en úlceras de pie diabético para lograr la granulación, los eventos adversos asociados al tratamiento presentan similares características a lo informado a nivel nacional e internacional.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  Heberprot-P is a novel drug that has come for the reduction of amputation risks; like any drug it is not devoid of adverse events.  Objectives:  to characterize patients during Heberprot-P treatment according to demographic and clinical variables, as well as to describe adverse events reported during therapy.  Methods:  a longitudinal study was conducted at the Comprehensive Care Clinic for patients with diabetic foot ulcers at "Policlínico Manuel Piti Fajardo" in Santo Domingo, Villa Clara, between January 2017 and September 2019. The sample was 104 patients who were applied the Heberprot-P. Variables used were: age, sex, Wagner's classification, etiopathogenic classification of the diabetic foot, treatment effectiveness and reported adverse events (frequency, intensity, severity and causality relationship were addressed).  Results:  females and patients over 60 years old predominated (67.31%). According to Wagner's classification for diabetic foot ulcer, grade 1 prevailed (73.08%), and according to etiopathogenesis, patients with neuroinfective foot prevailed (58.65%). Total effectiveness of treatment was 90.38%. The most frequent adverse events were burning, pain and headache. Adverse events dependent on the mode of administration and the product itself (burning and pain) predominated, mostly of mild intensity and defined causality.  Conclusions:  the beneficial effect of Heberprot-P in diabetic foot ulcers to achieve granulation was confirmed. Adverse events associated with treatment present similar characteristics to those reported at national and international level.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Heberprot-P]]></kwd>
<kwd lng="es"><![CDATA[pie diabético]]></kwd>
<kwd lng="es"><![CDATA[reacciones adversas]]></kwd>
<kwd lng="en"><![CDATA[Heberprot-P]]></kwd>
<kwd lng="en"><![CDATA[diabetic foot]]></kwd>
<kwd lng="en"><![CDATA[adverse reactions]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<collab>Centro Nacional de Información de Ciencias Médicas. Biblioteca Médica Nacional</collab>
<article-title xml:lang=""><![CDATA[Diabetes. Estadísticas Mundiales]]></article-title>
<source><![CDATA[Factográfico salud]]></source>
<year>2019</year>
<volume>5</volume>
<numero>6</numero>
<issue>6</issue>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<collab>International Diabetes Federation</collab>
<source><![CDATA[IDF Diabetes Atlas]]></source>
<year>2017</year>
<edition>8</edition>
<publisher-loc><![CDATA[Belgium ]]></publisher-loc>
<publisher-name><![CDATA[International Diabetes Federation]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="book">
<collab>Ministerio de Salud Pública. Dirección de Registros Médicos y Estadísticas de Salud</collab>
<source><![CDATA[Anuario Estadístico de Salud 2018]]></source>
<year>2019</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[MINSAP]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Son]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Yoo]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Cha]]></surname>
<given-names><![CDATA[BY]]></given-names>
</name>
<name>
<surname><![CDATA[Son]]></surname>
<given-names><![CDATA[HY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Low muscle mass and risk of type 2 diabetes in middle-aged and older adults: findings from the KoGES]]></article-title>
<source><![CDATA[Diabetologia]]></source>
<year>2017</year>
<volume>60</volume>
<numero>5</numero>
<issue>5</issue>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Domínguez Torres]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Hechavarría Espinosa]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ortiz González]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Suarez Rodríguez]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Polifarmacia en la tercera edad. Algunas consideraciones]]></article-title>
<source><![CDATA[Rev Electrón]]></source>
<year>2015</year>
<volume>38</volume>
<numero>5</numero>
<issue>5</issue>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Díaz Díaz]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Orlandi González]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<source><![CDATA[Manual para el diagnóstico y tratamiento del paciente diabético en el nivel primario de salud]]></source>
<year>2016</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[Editorial Ciencias Médicas]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Trujillo Pedrosa]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[George Arse]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ortega Sánchez]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Complicación que se presenta en los pacientes al tratamiento con Heberprot-p en un área de salud]]></article-title>
<source><![CDATA[Acta Méd Centro]]></source>
<year>2017</year>
<volume>11</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="book">
<collab>Infiltración del Heberprot-p</collab>
<source><![CDATA[Un tratamiento eficaz para la úlcera de pie diabético]]></source>
<year>2009</year>
<edition>2</edition>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[Editorial Elfos Scientiae]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fernández-Montequín]]></surname>
<given-names><![CDATA[JI]]></given-names>
</name>
<name>
<surname><![CDATA[Betancourt]]></surname>
<given-names><![CDATA[BY]]></given-names>
</name>
<name>
<surname><![CDATA[Leyva-Gonzalez]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Mola]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
<name>
<surname><![CDATA[Galán-Naranjo]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Ramírez-Navas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intralesional administration of epidermal growth factor-based formulation (Heberprot-P) in chronic diabetic foot ulcer: treatment up to complete wound closure]]></article-title>
<source><![CDATA[Int Wound J]]></source>
<year>2009</year>
<volume>6</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yera]]></surname>
<given-names><![CDATA[IB]]></given-names>
</name>
<name>
<surname><![CDATA[Alonso]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Álvarez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Debesa]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Postmarketing effectiveness and safety of Heberprot-P for diabetic foot ulcer treatment in Cuba]]></article-title>
<source><![CDATA[Biotecnol Apl]]></source>
<year>2010</year>
<volume>27</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brunton]]></surname>
<given-names><![CDATA[LL]]></given-names>
</name>
<name>
<surname><![CDATA[Lazo]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Parker]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
</person-group>
<source><![CDATA[Goodman-Gilman. Las bases farmacológicas de la terapéutica]]></source>
<year>2012</year>
<edition>12</edition>
<publisher-loc><![CDATA[DF ]]></publisher-loc>
<publisher-name><![CDATA[McGraw-Hill Interamericana]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Flórez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Farmacología Humana]]></source>
<year>2014</year>
<edition>6</edition>
<publisher-loc><![CDATA[Barcelona ]]></publisher-loc>
<publisher-name><![CDATA[Masson]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jiménez]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Alfonso]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Calvo]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Broche]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Lara]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Normas y procedimientos de trabajo del Sistema Cubano de Farmacovigilancia]]></source>
<year>2011</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[Unidad Coordinadora Nacional]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Inglés Maury]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez Inglés]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Serrano Frómeta]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Tudela Turcáz]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández Arnejo]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Terapéutica ambulatoria con Heberprot-P en pacientes con úlceras de pie diabético]]></article-title>
<source><![CDATA[Rev Inf Cient]]></source>
<year>2014</year>
<volume>87</volume>
<numero>5</numero>
<issue>5</issue>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[González Benavides]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez Mederos]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Peraltas Pérez]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Resultados de la utilización del heberprot-P(r)]]></article-title>
<source><![CDATA[Acta Méd Centro]]></source>
<year>2014</year>
<volume>8</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Verdaguer Pérez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Muguercia Silva]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Ayala Lafargue]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bertrán Bahades]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Estrada Ladoy]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Experiencias en el tratamiento con Heberprot-P(r) en pacientes con pie diabético]]></article-title>
<source><![CDATA[MEDISAN]]></source>
<year>2017</year>
<volume>21</volume>
<numero>8</numero>
<issue>8</issue>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Turns]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevention and management of diabetic foot ulcers]]></article-title>
<source><![CDATA[Br J Community Nurs]]></source>
<year>2015</year>
<volume>S30</volume>
<numero>S32</numero>
<issue>S32</issue>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guillermo]]></surname>
<given-names><![CDATA[Garelli]]></given-names>
</name>
<name>
<surname><![CDATA[Calvagno]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Tolstano]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Carrio]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bullo]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tratamientos de úlceras severas de pie diabético con factor de crecimiento epidérmico recombinante (Heberprot-p(r))]]></article-title>
<source><![CDATA[Rev Argent Cir Cardiovasc]]></source>
<year>2012</year>
<volume>10</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Montequin]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Valenzuela]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Savigne]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Gonzalez]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Sancho]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Rivero]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intra-lesional injections of recombinent human epidermal grounth factor promote granulation and healing in advanced diabetic foot ulcer: Multicenter, randomised, placebo-controllet-double-blind study]]></article-title>
<source><![CDATA[Int Wound J]]></source>
<year>2009</year>
<volume>6</volume>
<numero>6</numero>
<issue>6</issue>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Silva Pupo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[González Moya]]></surname>
<given-names><![CDATA[IA]]></given-names>
</name>
<name>
<surname><![CDATA[Valenciano García]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[González Cedeño]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evolución de lesiones complejas en el pie diabético con uso de Heberprot-P(r)]]></article-title>
<source><![CDATA[AMC]]></source>
<year>2015</year>
<volume>19</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Trujillo Pedroza]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[George Arce]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Valdés Morales]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Ortega Sánchez]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Mendoza Molina]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Resultados del Programa de atención integral al paciente con pie diabético]]></article-title>
<source><![CDATA[Acta Méd Centro]]></source>
<year>2018</year>
<volume>13</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Álvarez CrespoI]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Alonso Carbonell]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Yera Alós]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[García Milián]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Marrero Miragaya]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Caracterización de los eventos adversos reportados durante el tratamiento con Heberprot-P(r) en cuatro provincias de Cuba]]></article-title>
<source><![CDATA[Rev Horizonte Sanitario]]></source>
<year>2015</year>
<volume>14</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="confpro">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Navarro Despaigne]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes mellitus in the elderly from the foot to the head]]></source>
<year></year>
<conf-name><![CDATA[ VCongreso Internacional: Combatiendo la diabetes y sus complicaciones más severas]]></conf-name>
<conf-loc>Matanzas, 2018 </conf-loc>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Díaz Díaz]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[La importancia de desarrollar estructuras eficientes de educación terapéutica en pacientes con diabetes]]></article-title>
<source><![CDATA[Rev Cubana Endocrinol]]></source>
<year>2016</year>
<volume>27</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bakker]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Apelqvist]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lipsky]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
<name>
<surname><![CDATA[Van Netten]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[International Working Group on the Diabetic Foot. The IWGDF guidance on the management and prevention of foot problems in diabetes: development of an evidence-based global consensus]]></article-title>
<source><![CDATA[Diabetes Metab Res Rev]]></source>
<year>2016</year>
<volume>32</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
